COVID-19 in patients with severe asthma using biological agents

Creative Commons License

AKSU K., Demir Ş., Topel M., Yeşilkaya S., ATEŞ H., Koca Kalkan İ., ...Daha Fazla

Tuberkuloz ve Toraks, cilt.69, sa.3, ss.433-436, 2021 (ESCI, Scopus, TRDizin)

  • Yayın Türü: Makale / Teknik Not
  • Cilt numarası: 69 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5578/tt.20219721
  • Dergi Adı: Tuberkuloz ve Toraks
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CAB Abstracts, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.433-436
  • Anahtar Kelimeler: Severe asthma, omalizumab, mepolizumab, COVID-19
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

As the COVID-19 pandemic continues, case reports have been published where patients with severe asthma using biological agents survived with a mild course of illness and encouraged the continuation of biological therapies in patients with severe asthma. However, contrary to previous information, a more severe course of COVID-19 has recently been reported in severe asthmatics using biological therapy compared to the general population. A retrospective study was conducted in patients with severe asthma treated with biological agents. Data concerning whether the subjects had contracted COVID-19 and the severity of the disease were evaluated. Eighty-four severe asthmatics using biological agents (omalizumab or mepolizumab) aged 48.3 ± 10.6 years (mean ± standard deviation) with female/male ratio: 53 (63.1%)/31 (36.9%) were included in the study. Among participants 13 (15.5%) had contracted COVID-19. The course of COVID-19 was mild in five (38.5%) and moderate in eight patients (61.5%), while none of the patients had a severe course of COVID-19. Mechanical ventilation or intensive care follow-up was not required in any of the six patients (46.2%) who were treated as inpatients. All participants survived COVID-19 in full recovery and no deaths occurred in the cases. A higher rate of COVID-19 was found in patients with severe asthma using biologics compared to those reported in previous reports. However, all patients with COVID-19 have a mild to moderate disease course.